Recent research indicates that the popular diabetes medication, Ozempic, could potentially be manufactured for less than $5 each month. The pharmaceutical giant behind the drug, Novo Nordisk, currently charges about $1,000 per month for each injection in the United States, prior insurance reductions. This investigation was a collaboration between analysts from Yale University, King’s College Hospital in London, and the nonprofit humanitarian medical organization, Doctors Without Borders.
High Demand and High Costs
The findings of the study raises significant questions about the considerable cost of top-performing diabetes medicines and identical weight loss treatments, which are all categorized under a novel class of remedies known as GLP-1s. Over the last year, demand for these pharmaceuticals has escalated exponentially. Unfortunately, as a consequence of their high costs, an increasing number of insurance companies have decided to eliminate them from their coverage lists, leaving many patients unable to afford these essential treatments.
This research follows years of political pressure encouraging Novo Nordisk and similar pharmaceutical companies to decrease the exorbitant costs associated with diabetes care, particularly insulin. According to the study published in JAMA Network Open, Ozempic could be produced for less when compared with several forms of insulin.
Estimate Production Cost
The investigative team discovered that the cost to produce a monthly supply of Ozempic ranged from an estimated 89 cents to $4.73. These figures were derived by assessing the manufacturing costs for the weekly injection, incorporating a profit margin along with an allowance for tax to generate these “cost-based prices.”
In stark contrast, the list price for a monthly package of Ozempic from Novo Nordisk stands at a staggering $935.77 before any insurance or rebates are considered. The research concluded with the realization that GLP-1s may generally be manufactured for prices significantly lower than current rates, possibly offering wider access to the treatment.
However, Novo Nordisk refused to disclose the production costs for Ozempic and Wegovy, its weight loss drug variant. The Danish pharmaceutical firm did mention that it invested almost $5 billion in research and development during the previous year and plans to spend over $6 billion in a recent agreement to enhance manufacturing to meet the escalating demands for GLP-1s.
Affordability and Access
Novo Nordisk also noted that 75% of its gross earnings are directed toward rebates and discounts to ensure patients can access its products. The cost that a patient has to pay for Ozempic primarily relies on their individual insurance coverage. Patients with private or commercial coverage for Ozempic can avail of a savings card and pay just $25 for a one, two, or three-month supply of the treatment for up to 24 months.
In separate research conducted by the University of Liverpool, it was found that Wegovy could potentially be produced for about $40 per month. An Evercore ISI survey released this month found that over half of people currently prescribed a GLP-1 reported they are paying a monthly price of $50 or less out of pocket. Nearly 75% of respondents who used to take one of these medications said they spent an equivalent sum.
